| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
|
Lancet Oncol
|
2006
|
6.92
|
|
2
|
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
|
Cancer Cell
|
2012
|
6.71
|
|
3
|
Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
|
Nature
|
2012
|
4.13
|
|
4
|
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
|
Lancet Oncol
|
2013
|
2.82
|
|
5
|
End-of-life care preferences of pediatric patients with cancer.
|
J Clin Oncol
|
2005
|
2.66
|
|
6
|
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
|
J Clin Oncol
|
2005
|
2.19
|
|
7
|
Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature.
|
Cancer
|
2004
|
1.84
|
|
8
|
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
|
Clin Cancer Res
|
2006
|
1.58
|
|
9
|
Cytogenetic prognostication within medulloblastoma subgroups.
|
J Clin Oncol
|
2014
|
1.56
|
|
10
|
A prognostic gene expression signature in infratentorial ependymoma.
|
Acta Neuropathol
|
2012
|
1.44
|
|
11
|
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
|
J Clin Oncol
|
2013
|
1.43
|
|
12
|
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
|
J Neurooncol
|
2006
|
1.38
|
|
13
|
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
|
Acta Neuropathol
|
2013
|
1.35
|
|
14
|
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
1.18
|
|
15
|
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
|
Neuro Oncol
|
2008
|
1.15
|
|
16
|
Ependymoma: new therapeutic approaches including radiation and chemotherapy.
|
J Neurooncol
|
2005
|
1.15
|
|
17
|
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
|
Cancer
|
2005
|
1.12
|
|
18
|
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
|
Neuro Oncol
|
2011
|
1.05
|
|
19
|
Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.
|
J Clin Oncol
|
2008
|
1.05
|
|
20
|
Survival and late mortality in long-term survivors of pediatric CNS tumors.
|
J Clin Oncol
|
2007
|
1.05
|
|
21
|
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
|
J Clin Oncol
|
2006
|
1.03
|
|
22
|
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
|
J Clin Oncol
|
2004
|
1.02
|
|
23
|
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
|
Clin Cancer Res
|
2002
|
1.01
|
|
24
|
Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.
|
Cancer
|
2006
|
0.99
|
|
25
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
|
26
|
High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors.
|
Cancer
|
2008
|
0.97
|
|
27
|
Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes.
|
Am J Clin Pathol
|
2006
|
0.97
|
|
28
|
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
|
Nat Med
|
2015
|
0.91
|
|
29
|
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
|
Cancer Chemother Pharmacol
|
2003
|
0.91
|
|
30
|
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.90
|
|
31
|
Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts.
|
J Neurosurg Pediatr
|
2008
|
0.88
|
|
32
|
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
|
J Neurooncol
|
2014
|
0.87
|
|
33
|
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
|
Pediatr Blood Cancer
|
2013
|
0.87
|
|
34
|
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).
|
Clin Cancer Res
|
2013
|
0.86
|
|
35
|
Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
|
J Neurooncol
|
2014
|
0.86
|
|
36
|
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
|
Cancer
|
2009
|
0.85
|
|
37
|
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
|
Brain Pathol
|
2013
|
0.84
|
|
38
|
Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
|
J Neurooncol
|
2014
|
0.84
|
|
39
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
|
40
|
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
|
Clin Cancer Res
|
2010
|
0.82
|
|
41
|
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
|
J Neurooncol
|
2015
|
0.82
|
|
42
|
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
|
Clin Cancer Res
|
2002
|
0.81
|
|
43
|
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
|
Acta Neuropathol Commun
|
2014
|
0.79
|
|
44
|
Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS).
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
0.79
|
|
45
|
Training subspecialty nurses in developing countries: methods, outcome, and cost.
|
Med Pediatr Oncol
|
2003
|
0.79
|
|
46
|
Pediatric tectal plate gliomas: a review of clinical outcomes, endocrinopathies, and neuropsychological sequelae.
|
J Neurooncol
|
2015
|
0.79
|
|
47
|
Molecular biology of pediatric brain tumors and impact on novel therapies.
|
Curr Neurol Neurosci Rep
|
2015
|
0.79
|
|
48
|
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
|
Cancer Chemother Pharmacol
|
2015
|
0.77
|
|
49
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
50
|
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
51
|
Nocardia farcinica Meningitis Masquerading as Central Nervous System Metastasis in a Child With Cerebellar Pilocytic Astrocytoma.
|
J Pediatr Hematol Oncol
|
2015
|
0.75
|
|
52
|
Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.
|
Paediatr Drugs
|
2013
|
0.75
|
|
53
|
Polar spongioblastoma of the spinal cord: a case report.
|
Pediatr Dev Pathol
|
2006
|
0.75
|
|
54
|
Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor.
|
J Pediatr Hematol Oncol
|
2011
|
0.75
|
|
55
|
Medulloblastoma with melanotic differentiation: case report and review of the literature.
|
J Neurooncol
|
2010
|
0.75
|